Shares of Curis, Inc. (NASDAQ:CRIS) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $1.46 and last traded at $0.00, with a volume of shares trading hands.
A number of analysts have issued reports on CRIS shares. Guggenheim started coverage on shares of Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 target price for the company. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. ValuEngine cut shares of Curis from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Finally, BidaskClub cut shares of Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Curis has an average rating of “Hold” and a consensus price target of $6.50.
Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. Curis’s revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.09) earnings per share.
Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of Curis by 58.7% during the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 13,448 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of Curis during the 1st quarter worth approximately $105,000. OxFORD Asset Management LLP bought a new position in shares of Curis during the 2nd quarter worth approximately $115,000. Voya Investment Management LLC grew its stake in shares of Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 12,207 shares in the last quarter. Finally, American International Group Inc. grew its stake in shares of Curis by 7.1% during the 1st quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after acquiring an additional 4,560 shares in the last quarter. 44.72% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Curis, Inc. (CRIS) Hits New 52-Week Low at $1.46” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.com-unik.info/2017/11/02/curis-inc-cris-hits-new-52-week-low-at-1-46.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
What are top analysts saying about Curis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Curis Inc. and related companies.